Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 3 | 1 | — | — | 5 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | 3 | — | — | 5 |
Colorectal neoplasms | D015179 | — | — | 2 | 2 | 1 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 2 | — | — | — | 2 |
Squamous cell carcinoma | D002294 | — | — | — | 2 | — | — | — | 2 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Endometrioid carcinoma | D018269 | — | — | — | 1 | — | — | — | 1 |
Acinar cell carcinoma | D018267 | — | — | — | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 5 | — | — | — | — | 5 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | — | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Drug common name | Brivanib alaninate |
INN | brivanib alaninate |
Description | Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a prodrug, an apoptosis inducer, a fibroblast growth factor receptor antagonist and an angiogenesis inhibitor. It is a pyrrolotriazine, an aromatic ether, a fluoroindole, a diether, a carboxylic ester and a L-alanine derivative. It is functionally related to a brivanib. |
Classification | Small molecule |
Drug class | angiogenesis inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1 |
PDB | — |
CAS-ID | 649735-63-7 |
RxCUI | — |
ChEMBL ID | CHEMBL270995 |
ChEBI ID | — |
PubChem CID | 11154925 |
DrugBank | DB11865 |
UNII ID | U2Y5OFN795 (ChemIDplus, GSRS) |